Physician profile

Taylor E Tucker

Nurse Practitioner · Chattanooga, TN

NPI 1952736845

$501.83

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$103.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Optinose US, INC. $175.41 2021-2023
Genzyme Corporation $137.75 2021-2022
Abbvie INC. $47.13 2021-2022
Medtronic, INC. $36.85 2024 Ligasure
Glaxosmithkline, LLC. $34.79 2023 Nucala
Regeneron Healthcare Solutions, INC. $24.45 2022
Intersect Ent, INC. $16.61 2021
Alk-Abello, INC $15.20 2022
Merck Sharp & Dohme LLC $13.64 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Taylor E Tucker

$501.83

in general payments reported 2019-2025

Years
2021-2024
Top company
Optinose US, INC.

https://glasscript.com/doctor/10583297/taylor-e-tucker

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.